pharmaceutical monoclonal antibody

Adverse effects

• serum sickness-like reaction to murine light & heavy chain variable regions when monocloncal Ab is a chimeric mouse + human monoclonal Ab with the monoclonal Ab containing murine light & heavy chain & human constant region

• drug adverse effects of pharmaceutical monoclonal antibodies

More general terms

• monoclonal antibody
• pharmaceutical agent

More specific terms

• abciximab (ReoPro)
• adalimumab (Humira, Idacio, Yusimry, Yuflyma)
• alirocumab (Praluent)
• anifrolumab (Saphnelo)
• ansuvimab-zykl (Ebanga)
• anti-Alzheimer monoclonal antibody
• antineoplastic monoclonal antibody
• atoltivimab; atoltivimab
• axatilimab (Niktimvo)
• bapineuzumab
• basiliximab (Simulect)
• belimumab (Benlysta)
• benralizumab (Fasenra)
• bezlotoxumab (Zinplava)
• bimekizumab-bkzx
• bispecific antibody; bispecific monoclonal antibody
• bococizumab
• britumomab (Zevalin)
• brodalumab (Siliq)
• brolucizumab; brolucizumab-dbll (Beovu)
• burosumab
• canakinumab (Ilaris)
• caplacizumab-yhdp (Cablivi)
• certolizumab pegol (Cimzia)
• crizanlizumab
• crovalimab (Piasky)
• daclizumab (Zinbryta)
• denosumab (Prolia, Xgeva)
• depemokimab
• dupilumab (Dupixent)
• Ebola monoclonal antibody (ZMapp)
• eculizumab (Soliris)
• efalizumab (Raptiva)
• efgartigimod alfa-fcab (Vyvgart)
• emapalumab; emapalumab lzsg (Gamifant)
• emicizumab-kxwh (Hemlibra, ACE910)
• eptinezumab
• erenumab (Aimovig)
• evinacumab-dgnb (Evkeeza)
• evolocumab (Repatha)
• faricimab-svoa (Vabysmo)
• fremanezumab (Ajovy)
• frunevetmab (Solensia)
• galcanezumab (Emgality)
• gemtuzumab
• guselkumab (Tremfya)
• ibalizumab-uiyk (Trogarzo)
• idarucizumab (Praxbind)
• inebilizumab-cdon (Uplizna)
• infliximab (Remicade)
• itolizumab
• ixekizumab (Taltz)
• lanadelumab (Takhzyro)
• lebrikizumab (Ebglyss)
• ligelizumab
• maftivimab
• marstacimab (Hympavzi)
• mavrilimumab
• mepolizumab (Nucala)
• mirikizumab-mrkz (Omvoh)
• monoclonal antibody AMG 145
• monoclonal antibody combination
• monoclonal antibody SAR2365535
• monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)
• Muromonab-CD3 (OKT3)
• natalizumab (Tysabri)
• nemolizumab (Mitchga)
• nirsevimab-alip (Beyfortus)
• obiltoxaximab (Anthim)
• ocrelizumab (Ocrevus)
• odesivimab
• olokizumab
• omalizumab (Xolair)
• palivizumab (Synagis)
• pexelizumab
• Polatuzumab Vedotin (POLIVY)
• pozelimab-bbfg (Veopoz)
• prasinezumab
• ravulizumab (Ultomiris)
• raxibacumab
• reslizumab (Cinqair)
• rhuMAB-E25
• risankizumab (Skyrizi)
• romosozumab (Evenity)
• rozanolixizumab-noli (Rystiggo)
• sarilumab (Kevzara)
• satralizumab-mwge (Enspryng])
• secukinumab (Cosentyx)
• siltuximab (Sylvant)
• sintilimab
• spesolimab
• sutimlimab-jome (Enjaymo)
• tafasitamab-cxix (Monjuvi)
• teprotumumab-trbw (Tepezza)
• tezepelumab-ekko (Tezspire)
• tildrakizumab (Ilumya)
• tocilizumab; atlizumab (Actemra, RoActemra, Tofidence, Tyenne)
• tralokinumab-ldrm (Adbry, Adtralza)
• ublituximab (Briumvi)
• ustekinumab (Stelara, Wezlana, Pyzchiva, Selarsdi, Yesintek)
• vedolizumab (Entyvio)
• vilobelimab (Gohibic)